NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mmPotentially best-in-class durability with a favorable safety profile and no dose-limiting toxicityPhase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027Conference Call and Webcast today, March 09 at 9:00 AM ET ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or t
